Midwest Trust Co Invests $918,000 in Boston Scientific Corporation $BSX

Midwest Trust Co acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 8,549 shares of the medical equipment provider’s stock, valued at approximately $918,000.

Several other hedge funds have also made changes to their positions in BSX. 1248 Management LLC purchased a new position in Boston Scientific during the first quarter valued at approximately $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific during the 1st quarter valued at $27,000. Sound Income Strategies LLC grew its holdings in shares of Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares in the last quarter. Princeton Global Asset Management LLC acquired a new position in shares of Boston Scientific in the second quarter worth $32,000. Finally, Oliver Lagore Vanvalin Investment Group purchased a new stake in shares of Boston Scientific during the second quarter worth $37,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on BSX shares. Canaccord Genuity Group restated a “buy” rating and issued a $132.00 price objective on shares of Boston Scientific in a report on Thursday, October 23rd. Raymond James Financial raised their target price on Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a report on Thursday, July 24th. BTIG Research reiterated a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a research note on Wednesday, October 22nd. The Goldman Sachs Group reissued a “buy” rating and issued a $124.00 price objective on shares of Boston Scientific in a research note on Wednesday, October 22nd. Finally, Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 11th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific has an average rating of “Buy” and a consensus target price of $123.77.

Boston Scientific Stock Up 1.6%

BSX opened at $102.53 on Wednesday. The company has a market capitalization of $151.99 billion, a P/E ratio of 54.83, a P/E/G ratio of 2.02 and a beta of 0.58. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The firm’s fifty day moving average price is $99.92 and its two-hundred day moving average price is $102.53. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The business had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same period in the prior year, the firm posted $0.63 EPS. Boston Scientific’s quarterly revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This represents a 21.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 175,782 shares of company stock worth $17,742,314 in the last 90 days. Company insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.